Growth Failure Clinical Trial
Official title:
Evaluation of the Normal Range of Urinary Sodium Levels in Healthy Newborn Babies
Oral sodium supplementation is currently administered in cases of poor weight gain in
infants particularly in patients who have undergone gastrointestinal surgical procedures.
The decision to start oral supplementation is based on urinary sodium levels although the
level at which to start treatment is variable as the range in normal, healthy infants is
unknown. This study aims to ascertain the normal range of sodium in urine specimens
collected from healthy newborn babies.
It is believed that by increasing the level of salt in the intestine, glucose can be more
easily be absorbed and therefore weight gain improved. Babies with conditions where they are
at risk of salt depletion (i.e. those with a stoma) are currently administered oral sodium
supplementation if they are failing to gain weight and have an associated 'low' urinary
sodium level. Low levels of urinary sodium are considered to represent a state of low body
sodium levels, as the kidneys attempt to reabsorb most of the sodium in the urine before it
is excreted.
Current practice varies widely as to the level below which treatment should be instigated.
Some centres advise below 20 mmol/L (Birmingham Children's Hospital and Nottingham
Children's Hospital guidelines), others below 10 mmol/L (University Children's Hospital,
Zurich). In Glasgow, babies with poor weight gain are given sodium supplementation if
urinary sodium levels are below 40 mmol/L. There are no documented ranges for the levels of
urinary sodium in healthy, newborn babies.
By determining the reference range of urinary sodium levels in healthy, term babies who are
gaining weight appropriately, the investigators hope to be able to have a better
understanding about both the level below which supplementation should be considered and the
target range that should be aimed for.
Study design
The study has been designed as a cross sectional study where participants details are
recorded at birth, followed by a second time point at 6 weeks of age when a corresponding
sample of urine will be obtained. The population being studied is healthy term (37-41 week
gestation) babies with no significant ante- or post-natal history born within the study
period in a single maternity unit. Participants will be required to collect a sample of
urine at 6 weeks post-natal age (they will be provided with a standardized means to collect
the specimen) and return it to the investigators in a pre-paid, pre-addressed envelope
(UN602 compliant packaging). This design has been chosen to obtain an unbiased sample group,
with minimal inconvenience or risk to participants. All confounding factors will be measured
on a data-sheet accompanying the specimen (sex, weight, method of feeding and medications).
The study should not be susceptible to bias as there is no perceived association between
those participants who either wish to take part in the study or subsequently choose to
collect and return the specimen, and their baby's urinary sodium level.
Prospective participants will be identified and approached by the neonatal/maternity staff
at the pre-discharge routine baby check (see Inclusion/Exclusion criteria) from the starting
date of the study for a period of 3 months (estimate based on average newborn deliveries per
week and expected return yield of urinary sodium samples i.e. participant drop-out rate).
There will be no coercion to participate. Mothers will be supplied with a patient
information statement and informed consent obtained. The consent will be filed in the
mother's medical notes and there will be no means of identification on the consent form that
will link it with any specimen obtained from the mother's baby. Instead, it will be a
generic form indicating intent to participate in the study. If mothers do wish to take part
in the study, an initial data-set will be obtained that will be identified by a unique study
participation number. This will include sex of the baby, birth weight, intended method of
feeding/milk and any medication. A study pack will be issued containing a set of
instructions outlining the study, a gender-specific urine collection bag, a specimen pot
labeled with the participant's unique identifying number (into which the urine sample should
be transferred prior to returning it), the data-set collection form and pre-paid,
pre-addressed envelope (UN602 compliant packaging) in which to return the specimen and
completed form.
It will be made clear to all participants that they are free to withdraw from the study for
any reason at any stage and that this will not affect their future care. No attempts will be
made to contact the families if samples are not returned after the 6 week time period.
There is no planned interim analysis. The study will continue until sufficient samples have
been returned in order to complete meaningful statistical analysis. It is anticipated that
this study should last no longer than 3 months.
Safety analysis
Participation in the study is not deemed to involve any risk for patients, their families or
staff involved.
Sample size and estimation
135 participants recruited over 3 months. An independent statistician has been consulted.
The sample size or reference limits has been based upon the precision of the confidence
intervals around each limit. On computing a 95% reference interval based on a normal
distribution (with reference limits to be at most 15% of the reference interval size) gives
a sample size of 135.
A dropout rate of at least 25% is expected, and therefore, in order to achieve an adequate
sample size, we intend to pause the study after 200 participants have enrolled. If less than
135 samples are returned within 6 weeks after the final participant is enrolled, then
further participants will be recruited to achieve the desired sample size.
Sample analysis
Urinary electrolytes will be measured in the Biochemistry laboratory in the Royal Hospital
for Sick Children. Urinary electrolytes (potassium, sodium and chloride) are measured by
in-direct (diluted) ion-selective electrodes (ISEs) which utilize membranes selective for
each ion species. A set volume of urine (15 ul) is diluted with diluent. A measuring
electrode is then submersed in this solution. An electrical potential (voltage) is developed
across the membranes between the reference and measuring electrodes in accordance with the
Nernst equation. The measured voltage is compared to previously determined calibrator
voltages and converted into ion concentrations (mmol/L).
Following analysis samples will be disposed in accordance with the Human Tissue Authority's
Code of Practice.
Statistical analysis
The variation of urinary sodium for the cohort will be presented as a normal range.
The urinary sodium of children who have not achieved a satisfactory weight gain will be
compared with those who have by a standard t test (as long as the urinary sodium values are
normally distributed).
Study closure
The study will end if any one of the following criteria is met:
- The planned sample size has been achieved
- There is insufficient funding to support further recruitment, and no reasonable
prospect of additional support being obtained
Ethical Consideration
The study will be carried out in accordance with the World Medical Association Declaration
of Helsinki (1964) and its revisions (Tokyo [1975], Venice [1983], Hong Kong [1989], South
Africa [1996] and Edinburgh[2000]). Favourable ethical opinion will be sought from an
appropriate Research and Ethics Committee (REC) before patients are entered into this study.
Patients will only be allowed to enter the study once either they have provided written
informed consent or their next of kin have provided written informed consent. The Chief
Investigator (CI) will be responsible for updating the Ethics committee of any new
information related to the study.
Finance and indemnity
This study is currently not sponsored. As the study is not deemed to confer risk to
participants, their families or staff, indemnity has not been sought.
Dissemination of results
It is not the intent of the researchers to inform the participants of the results of the
study. Firstly, all of the specimens collected and analyzed during the study are
unidentifiable there will be no way of contacting those who have taken part in the research
project. Secondly, the question that the study is designed to answer has no direct impact on
the care of any of the participants. Instead, the researchers aim to present their results
at a specialty-specific conference (e.g. British Association of Paediatric Surgeons annual
congress) and in an appropriate peer-reviewed journal, regardless of the outcome of the
results.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04226586 -
Nutritional Stimulation of Growth in Children With Short Stature
|
N/A | |
Active, not recruiting |
NCT01809548 -
Preterm Infants on Early Solid Foods
|
N/A | |
Completed |
NCT01475357 -
Intestinal Function in Neonates With Complex Congenital Heart Disease
|
N/A | |
Completed |
NCT02136966 -
Joint Infant and Young Child Nutrition Program and Malnutrition Prevention
|
N/A | |
Active, not recruiting |
NCT04565314 -
ELICIT 2.0: Pilot Study of the Effect of Maternal Protein Supplementation During Lactation on Childhood Growth
|
N/A | |
Recruiting |
NCT04809350 -
Human Milk Fortification With Adjustable Versus Targeted Method
|
N/A | |
Completed |
NCT02515266 -
Additional Protein Fortification in Extremely Low Birth Weight Infants
|
N/A | |
Recruiting |
NCT04294368 -
Targeted Fortification of Donor Breast Milk in Preterm Infants
|
N/A | |
Terminated |
NCT03532555 -
Enteral Zinc to Improve Growth in Infants at Risk for Bronchopulmonary Dysplasia
|
N/A | |
Withdrawn |
NCT02999945 -
Optimal Growth of Preterm Infants With Growth Restriction
|
N/A | |
Completed |
NCT01909661 -
Tolerance of Infants With Cow's Milk Protein Allergy to Extensively Hydrolyzed Rice Protein or Casein Infant Formulas
|
Phase 2 | |
Not yet recruiting |
NCT04640805 -
Targeted Fortification of Pasteurized Donor Human Milk
|
N/A | |
Completed |
NCT01603368 -
Prophylactic Probiotics to Extremely Low Birth Weight Prematures
|
Phase 2 | |
Withdrawn |
NCT01314508 -
Increlex Treatment of Children With Chronic Liver Disease and Short Stature
|
N/A | |
Terminated |
NCT00490100 -
Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1
|
Phase 1/Phase 2 | |
Completed |
NCT04587271 -
Nutritional Impact of Moringa Oleifera Leaf Supplementation in Mothers and Children
|
N/A | |
Completed |
NCT01034735 -
r-hGH Liquid Multidose Versus Freeze-dried Multidose Bioequivalence Trial
|
Phase 1 | |
Active, not recruiting |
NCT03761498 -
Is There a Microbiome Associated With Poor Growth in Preterm Infants?
|
||
Not yet recruiting |
NCT03522558 -
Medical Nutrition Therapy for Medically Complex Infants in the Pediatric Outpatient Setting
|
N/A | |
Completed |
NCT03563391 -
A Study to Evaluate the Effects of a New Formula on the Growth, Safety and Tolerance of Infants With Growth Failure
|
N/A |